Drug Trial Radar · NCT03786926
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
53
Actual
Start
Aug 26, 2019
Primary completion
Jun 26, 2024
Study completion Jun 26, 2024
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
Conditions
- Lymphoma
Interventions
HMPL-689Drug
HMPL-689 is a PI3Kδ inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1 (each cycle is 28 days)
- Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events (TEAEs), Treatment Related Treatment-Emergent Adverse Events (TRAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Related Serious Adverse Events (TRSAEs)Time frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 34 months
- Dose Expansion Stage: Number of Patients With Treatment-Emergent Adverse Events and Treatment Related Treatment-Emergent Adverse EventsTime frame: From the first dose of study drug (Day 1) up to 30 days after the last dose of study drug, approximately 27 months
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
Innovative Clinical Research Institute
Anaheim, California
Pacific Cancer Medical Center
Anaheim, California
Ventura County Hematology-Oncology Specialists
Oxnard, California
Winship Cancer Institute of Emory University
Atlanta, Georgia
Clinical Research Alliance, Inc
Westbury, New York
Levine Cancer Institute- Atrium Health
Charlotte, North Carolina
Baylor Scott and White Research Institute
Dallas, Texas
Renovatio Clinical
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Medical Oncology Associates, P.S.
Spokane, Washington
Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Tampereen yliopistollinen sairaala
Tampere, Finland
CHU de Nantes - Hotel Dieu
Nantes, France
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, France
Hopital Henri Mondor
Créteil, Val De Marne, France
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy
Ospedale San Raffaele
Milan, Italy
KO-MED Centra Kliniczne
Biała Podlaska, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
BioResearch Group Sp. Z. o. o.
Krakow, Poland
NASZ LEKARZ Osrodek Badan Klinicznych
Torun, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego
Wroclaw, Poland
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.